VIDEO: AML therapy regimens offer flexibility to fit patient needs
Noah Merin, MD, PhD
Disclosures
Merin reports he will be a speaker for Servier.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Well, that's the main thing about being an AML doctor is figuring out how to do that, and working with patients. So some of it is empiric.
A standing ovation for RevMed, and caution for Akeso
Breakthrough offers new hope for patients with relapsed blood cancer
ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
A turning point for pancreatic cancer patients
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
Practice-changing results reported for Revolution Medicines pancreatic cancer drug
At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
VIDEO: Minimal residual disease tests may ‘better match’ patients with care in AML
VIDEO: Triple therapy regimens being explored for acute myeloid leukemia
In this video, Adriana Rossi, MD, assistant professor of medicine at Mount Sinai, highlights challenges in multiple myeloma…
VIDEO: CAR-T in the frontline setting, other promising areas of research in myeloma
VIDEO: Immunotherapies offer new opportunities in relapsed, refractory myeloma
VIDEO: Treatment options vary for relapsed, refractory multiple myeloma
